DeepTrace Technologies is the first spin-off of IUSS, founded in 2020. The company’s vision is to promote a future in which healthcare innovations based on artificial intelligence make personalized, timely diagnosis, prognosis, and treatment accessible to everyone for a wide range of diseases and clinical conditions.

DeepTrace supports healthcare institutions with cutting-edge AI technologies capable of detecting diseases at their earliest stages, facilitating proactive interventions and improving patient outcomes.

The artificial intelligence platform offers a transformative approach to the diagnosis and prognosis of multifactorial diseases and enables faster therapeutic development. DeepTrace collaborates with healthcare organizations, medical device companies, and the pharmaceutical industry to improve diagnostic devices and clinical trials, accelerate diagnosis and therapy development, and ultimately bring effective diagnostic tools and treatments to market more quickly for various diseases and clinical conditions.